SCHEMBL6434819

SCHEMBL6434819

O=CNc1ccc(Cc2ccc(NC=O)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
LMNA P02545 4/20 0.45
HPGD P15428 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HTT P42858 2/20 0.45
KDM4E B2RXH2 1/20 0.45
SAE1 Q9UBE0 2/20 0.41
UBA2 Q9UBT2 2/20 0.41
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 3/20 0.38
CYP3A4 P08684 2/20 0.38
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14855299 0.91 ALDH1A1 (0.64) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL11915177 0.91 ALDH1A1 (0.46) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL12230601 0.89 ALDH1A1 (0.56) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL14403087 0.89 ALDH1A1 (0.45) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL17905782 0.88 ALDH1A1 (0.43) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL12882555 0.88 TSHR (0.54) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL12604863 0.84 POLB (0.50) ALDH1A1LMNAHPGDSAE1UBA2
SCHEMBL469386 0.84 ALDH1A1 (0.72) ALDH1A1LMNASMN1; SMN2KDM4EMEN1
SCHEMBL11915176 0.83 CYP3A4 (0.69) ALDH1A1LMNAHPGDSMN1; SMN2HTT
SCHEMBL17489435 0.83 TSHR (0.63) ALDH1A1LMNAHPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4342473-A2 COMPOUNDS USEFUL IN HIV THERAPY GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-03-27 EP disclosed
US-20240051972-A1 Compounds Useful in HIV Therapy GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-02-15 US disclosed
US-11873310-B2 Compounds useful in HIV therapy GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-01-16 US disclosed
US-11492361-B2 Compounds useful in HIV therapy GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-08 US disclosed
US-20220119417-A1 Compounds Useful in HIV Therapy GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-04-21 US disclosed
EP-2204408-B1 POLYOLEFIN RESIN COMPOSITION ADEKA CORP (JP) 2015-02-25 EP disclosed
WO-2014209934-A1 THERMOPLASTIC POLYURETHANE AND ASSOCIATED METHOD AND ARTICLE SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2014-12-31 WO disclosed
US-8853443-B2 Process for preparing an isocyanate BASF SE (DE) 2014-10-07 US disclosed
US-8853443-B2 Process for preparing an isocyanate BASF SE (DE) 2014-10-07 US disclosed
EP-2367783-B1 METHOD FOR PRODUCING AN ISOCYANATE BASF SE (DE) 2013-01-09 EP disclosed
US-4783500-A ORGANO-SILICON,-TIN, OR -GERMANIUM INITIATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-11-08 US disclosed
US-4711942-A FROM ACRYLIC OR MALEIMIDE MONOMER AND ORGANOSILICON,-TIN, OR -GERMANIUM INITIATOR E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-08 US disclosed
EP-0103968-B1 FORTIFIER FOR EPOXY RESINS, METHOD FOR THE PREPARATION THEREOF AND FORTIFIED EPOXY RESIN COMPOSITIONS CONTAINING SAME Canadian Patents and Development Limited Société Canadienne des Brevets et d'Exploitation Limitée (CA) 1987-07-22 EP disclosed
US-4581428-A Process for preparing \"living\" polymers using tetracoordinate organosilicon, organotin or organogermanium polymerization initiator with bifluoride ion source co-catalyst E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-04-08 US disclosed
US-4532259-A Protect industrial material against attack by fungi, bacteria, insects BAYER AKTIENGESELLSCHAFT (DE) 1985-07-30 US disclosed
EP-0145263-A1 Living polymers and process for their preparation E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-06-19 EP disclosed
US-4480082-A Epoxy resin fortifiers based on aromatic amides CANADIAN PATENTS & DEVELOPMENT LIMITED (CA) 1984-10-30 US disclosed
EP-0103968-A1 Fortifier for epoxy resins, method for the preparation thereof and fortified epoxy resin compositions containing same Canadian Patents and Development Limited Société Canadienne des Brevets et d'Exploitation Limitée (CA) 1984-03-28 EP disclosed
EP-0083015-A1 Bis-(fluoro and chloromethyl thioformamide), preparation and use thereof BAYER AG (DE) 1983-07-06 EP disclosed
US-3949559-A Process for isolating aqueous brine layers in underground gas-storage caverns BERGWERKSVERBAND GMBH (DT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119417-A1 Compounds Useful in HIV Therapy CD4, CCR5, ABCB1 ALDH1A1 424/4885LMNA 2214/4885HPGD 345/4885
US-20240051972-A1 Compounds Useful in HIV Therapy CD4, CCR5, ABCB1 ALDH1A1 424/4885LMNA 2214/4885HPGD 345/4885
US-11873310-B2 Compounds useful in HIV therapy CD4, CCR5, ABCB1 ALDH1A1 424/4885LMNA 2214/4885HPGD 345/4885
US-11492361-B2 Compounds useful in HIV therapy CD4, CCR5, ABCB1 ALDH1A1 474/4885LMNA 2648/4885HPGD 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.